ME Therapeutics Announces the Start of Testing of First mRNA Formulations from NanoVation Therapeutics Collaboration
ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology ...
BCBusiness3d
UBC’s NanoVation Therapeutics inks US$600 million deal with Novo Nordisk
The agreement with NanoVation marks the second big recent deal that a B.C. biotech startup has struck with the Danish ...
Business Wire5d
NanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk to Develop Genetic Medicines Targeting Cardiometabolic and Rare Diseases
VANCOUVER, British Columbia--(BUSINESS WIRE)--NanoVation Therapeutics, a platform company developing innovative technologies to overcome the barriers of nucleic acid delivery, today announced a ...
Financial Post5d
NanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk to Develop Genetic Medicines Targeting Cardiometabolic and Rare Diseases
Partnership focuses on enabling nucleic acid delivery to cells outside of the liver VANCOUVER, British Columbia — NanoVation Therapeutics, a platform company developing innovative technologies to ...
Vancouver3d
Vancouver biotech inks $800M partnership with Novo Nordisk
NanoVation Therapeutics, a Vancouver company co-founded by biotech magnate Pieter Cullis, has struck a partnership with ...
Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications
Canada-based NanoVation Therapeutics announced a multi-year partnership with Novo Nordisk A/S (NYSE:NVO) to advance the ...
FierceBiotech4d
Novo Nordisk bets $600M biobucks on NanoVation's ability to take genetic medicines beyond the liver
Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...
The Pharma Letter4d
NanoVation inks genetic medicines deal with Novo Nordisk
Canada’s NanoVation Therapeutics has partnered with Novo Nordisk to advance genetic medicines for cardiometabolic and rare ...
BioWorld4d
Nanovation Therapeutics partners with Novo Nordisk on genetic medicines for cardiometabolic and rare diseases
Nanovation Therapeutics Inc. has established a multiyear partnership with Novo Nordisk A/S to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases. The ...